AdvanCell

company

About

AdvanCell is radiopharmaceutical firm that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment.

  • Sydney,New South Wales,Australia
  • 11 - 50

Details

Last Funding Type
Series B
Last Funding Money Raised
$18M
Industries
Biotechnology,Clinical Trials,Pharmaceutical
Founded date
Jan 1, 2019
Number Of Employee
11 - 50
Operating Status
Active
Legal Name
AdvanCell Isotopes Pty Ltd.

AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$18M $2.10M
AdvanCell has raised a total of $18M $2.10M in funding over 2 rounds. Their latest funding was raised on Aug 23, 2022 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 23, 2022 Series B $18M 1 Morningside Venture Investments Detail
Dec 23, 2021 Grant $2.10M 1 NSW Health Detail

Investors

Number of Lead Investors
Number of Investors
2
2
AdvanCell is funded by 2 investors. Morningside Venture Investments and NSW Health are the most recent investors.
Investor Name Lead Investor Funding Round
Morningside Venture Investments Yes Series B
NSW Health Yes Grant

Employee Profiles

Number of Employee Profiles
1
AdvanCell has 1 current employee profiles, including Board member Anthony Aiudi
Board member